followed by 0.6 mg an hour later, with ongoing antiinflammatory therapy until the flare resolves). Based on similar efficacy between agents demonstrated in the NMA , the Voting Panel did not further prioritize between the first-line agents, noting that treatment selection should be driven by patient factors (e.g., comorbidity, access, past experience) as part of shared decisionmaking. Likewise, parenteral glucocorticoids were favored over alternative agents when oral dosing is not possible. In